TG Therapeutics receives Breakthrough Therapy Designation from FDA for umbralisib
TG Therapeutics announced the FDA has granted Breakthrough Therapy Designation for umbralisib (TGR-1202) for the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20 regimen. There are currently no fully approved agents for MZL. January 22, 2019